• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[双腔中心静脉导管功能不良管腔的肝素推注对血液透析期间活化部分凝血活酶时间的影响:是否需要额外肝素化?]

[The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].

作者信息

Sefer Sinisa, Kes Petar, Raić Biserka, Heinrich Branko, Degoricija Vesna, Szavits-Nossan Janko

机构信息

Zavod za nefrologiju i dijalizu, Klinicka bolnica Sestre milosrdnice, Zagreb, Hrvatska.

出版信息

Acta Med Croatica. 2006 Jun;60(3):281-5.

PMID:16933844
Abstract

AIM

The aim of the study was to determine the influence of the heparin bolus, which was administered to a patient due to incapability to aspire heparin from the dysfunctional lumen of dual lumen central venous catheter (CVK), on activated partial thromboplastin time (APTT) values during hemodialysis (HD), as well as to determine the need of additional administration of heparin during HD.

PATIENTS AND METHODS

The first group of examinees consisted of 19 patients with chronic renal failure (CRF) on whom the dual lumen CVK was applied as temporary vascular access, whereby the aspiration of heparin from one of its lumens was impossible. Prior to HD, a coagulogram was determined for all the patients. The testing of this group was carried out in accordance with two different protocols: protocol A and protocol B. Under protocol A, 7,500 IU of unfractioned heparin was injected into the patients' circulation from the dysfunctional lumen of CVK. During the four-hour HD process, APTT were determined after ten minutes, after hours 1, 2 and 3, and at the end of HD. During HD, no heparin was administered and every hour during HD there was visual evidence of blood clots in portions of the extracorporeal circuit system. Under protocol B, the APTT values were determined in the same group of patients according to the previous protocol, with the exception of 750 IU of heparin per hour being administered by continuous infusion to the patients during hours 3 and 4. The second group of examinees consisted of patients with CRF who have undergone dialysis via an arteriovenous fistula, while the testing was carried out under protocol C. The examinees in this group received a bolus of 2,500 IU of heparin at the beginning of HD, followed by a continuous administration of 750 IU of heparin per hour during the first three hours of HD (a total of 4,750 IU during the entire HD). During hour 4, HD was carried out without the administration of heparin. The protocol of determining APTT was identical to that carried out on the previous group of patients.

RESULTS

APTT values prior to HD: A=34.5 +/- 4.27 sec., B=32.38 +/- 4.16 sec. (p=0.457), C=33.66 +/- 3.63 sec. (p=0.245 in relation to protocol A and p=0.281 in relation to protocol B). APTT values ten minutes after the administration of the heparin bolus: A=210 +/- 21.42 sec., B=204.83 +/- 20.82 sec. (p=0.453), C=47.88 +/- 4.26 sec. (p=0.000 in relation to protocols A and B). APTT values after one hour: A=156 +/- 32.76 sec., B=159.66 +/- 30.39 sec. (p=0.377), C=43.88 +/- 4.5 sec. (p=0.000 in relation to protocols A and B). APTT values after two hours: A=81.54 +/- 0.41 sec., B=74.61 +/- 36.39 sec. (p=0.331), C=40.55 +/- 5.29 sec. (p=0.000 in relation to protocols A and B). APTT values after three hours: A=49.6 +/- 8.38 sec., B=59 +/- 8.93 sec. (p=0.395), C=37.88 +/- 2.58 sec. (p=0.000 in relation to protocols A and B). APTT values at the end of HD: A=40.5 +/- 3.97 sec., B=51.44 +/- 5.07 sec. (p=0.154), C=36.66 +/- 4.22 sec. (p=0.399 in relation to protocol A and p=0.222 in relation to protocol B). Clotting was noticed during the third hour of HD in 11 (57.89%) patients under protocol A, in two (10.5%) patients under protocol B and in three (15.78%) patients under protocol C. After comparing proportions for protocols A and C p=0.02, for protocols B and C p=0.998 and for protocols A and B p=0.006

CONCLUSION

Patients who received the heparin bolus from the dysfunctional lumen of dual lumen CVK needed an additional administration of heparin during hours 3 and 4 of HD in order to reduce the frequency of clotting in the extracorporeal circuit system. The frequency of clotting during HD in this study was not dependent on the total dosage of administered heparin, but rather on the means of its administration.

摘要

目的

本研究旨在确定因双腔中心静脉导管(CVK)功能异常管腔无法抽吸肝素而给予患者肝素推注对血液透析(HD)期间活化部分凝血活酶时间(APTT)值的影响,并确定HD期间额外给予肝素的必要性。

患者和方法

第一组受试者由19例慢性肾衰竭(CRF)患者组成,双腔CVK作为临时血管通路应用于他们,其中一个管腔无法抽吸肝素。HD前,为所有患者测定凝血图。该组测试按照两种不同方案进行:方案A和方案B。按照方案A,从CVK功能异常管腔向患者循环中注入7500 IU普通肝素。在4小时的HD过程中,分别在10分钟、第1、2和3小时以及HD结束时测定APTT。HD期间,未给予肝素,且HD期间每小时可见体外循环系统部分有血凝块。按照方案B,同一组患者根据先前方案测定APTT值,不同之处在于在第3和4小时期间每小时向患者持续输注750 IU肝素。第二组受试者由通过动静脉内瘘进行透析的CRF患者组成,测试按照方案C进行。该组受试者在HD开始时给予2500 IU肝素推注,随后在HD的前三个小时每小时持续给予750 IU肝素(整个HD期间共4750 IU)。在第4小时,HD过程中不给予肝素。测定APTT的方案与前一组患者相同。

结果

HD前APTT值:A = 34.5±4.27秒,B = 32.38±4.16秒(p = 0.457),C = 33.66±3.63秒(与方案A相比p = 0.245,与方案B相比p = 0.281)。给予肝素推注10分钟后APTT值:A = 210±21.42秒,B = 204.83±20.82秒(p = 0.453),C = 47.88±4.26秒(与方案A和B相比p = 0.000)。1小时后APTT值:A = 156±32.76秒,B = 159.66±30.39秒(p = 0.377),C = 43.88±4.5秒(与方案A和B相比p = 0.000)。2小时后APTT值:A = 81. .54±0.41秒,B = 74.61±36.39秒(p = 0.331),C = 40.55±5.29秒(与方案A和B相比p = 0.000)。3小时后APTT值:A = .49.6±8.38秒,B = 59±8.93秒(p = 0.395),C = 37.88±2.58秒(与方案A和B相比p = 0.000)。HD结束时APTT值:A = 40.5±3.97秒,B = 51.44±5.07秒(p = 0.154),C = 36.66±4.22秒(与方案A相比p = 0.399,与方案B相比p = 0.222)。按照方案A,11例( .57.89%)患者在HD第3小时出现凝血,按照方案B,2例(10.5%)患者出现凝血,按照方案C,3例(15.78%)患者出现凝血。比较方案A和C的比例,p = 0.02,方案B和C的比例,p = 0.998,方案A和B的比例,p = 0.006

结论

从双腔CVK功能异常管腔接受肝素推注的患者在HD的第3和4小时需要额外给予肝素,以降低体外循环系统凝血频率。本研究中HD期间的凝血频率不取决于肝素的总给药剂量,而是取决于给药方式。

相似文献

1
[The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].[双腔中心静脉导管功能不良管腔的肝素推注对血液透析期间活化部分凝血活酶时间的影响:是否需要额外肝素化?]
Acta Med Croatica. 2006 Jun;60(3):281-5.
2
Inadvertent postdialysis anticoagulation due to heparin line locks.因肝素封管导致的透析后意外抗凝。
Hemodial Int. 2007 Oct;11(4):430-4. doi: 10.1111/j.1542-4758.2007.00213.x.
3
[Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].[低分子肝素预防血液透析体外循环血栓形成:具有更佳出血风险/有效性比的剂量标准化]
Acta Med Port. 1992 Feb;5(2):65-70.
4
Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.血液透析过程中凝血的激活:单独血路及整个体外循环的影响。
Artif Organs. 2006 Feb;30(2):106-10. doi: 10.1111/j.1525-1594.2006.00188.x.
5
Comparison of PT, aPTT, and factor VII values obtained by concurrent sample collection by direct venipuncture and peripheral venous catheters.通过直接静脉穿刺和外周静脉导管同时采集样本所获得的凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)和凝血因子 VII 值的比较。
Pharmacotherapy. 1994 Mar-Apr;14(2):224-8.
6
Clinical consequences of heparin-free hemodialysis.无肝素血液透析的临床后果
Hemodial Int. 2005 Oct;9(4):393-8. doi: 10.1111/j.1542-4758.2005.01158.x.
7
Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.在有出血风险的患者中使用结合肝素的Hemophan进行血液透析。
Nephron Clin Pract. 2004;97(1):c5-10. doi: 10.1159/000077589.
8
Low-dose heparin retention in temporary hemodialysis double-lumen catheter does not increase catheter occlusion and might reduce risk of bleeding.临时血液透析双腔导管中低剂量肝素保留不会增加导管堵塞的风险,反而可能降低出血风险。
Blood Purif. 2011;32(3):232-7. doi: 10.1159/000328743. Epub 2011 Aug 9.
9
Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.低温体外循环后肝素清除装置与鱼精蛋白相比的疗效
ASAIO J. 1997 Sep-Oct;43(5):M825-30.
10
Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters.从肝素化的希克曼导管中丢弃临床有用的凝血研究所需的血量。
Oncol Nurs Forum. 1996 May;23(4):671-5.